New CAR-T therapy takes on toughest rheumatoid arthritis cases
NCT ID NCT07315503
First seen Jan 04, 2026 · Last updated May 06, 2026 · Updated 18 times
Summary
This early-stage study tests a treatment called GC012F in 9 adults with difficult-to-treat rheumatoid arthritis. The therapy uses a person's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and measure how long the cells stay in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, China
Conditions
Explore the condition pages connected to this study.